Brief: Perspective Therapeutics Expands Therapeutic Focus Areas First Patient Dosed With Vmt-Α-Net In The Meningioma Cohort Of A Phase 1/2A Study
03/06/2026 11:52
BRIEF-Perspective Therapeutics Expands Therapeutic Focus Areas First Patient Dosed With [212Pb]Vmt-Α-Net In The Meningioma Cohort Of A Phase 1/2A Study June 3 (Reuters) - Perspective Therapeutics Inc CATX.A:
PERSPECTIVE THERAPEUTICS EXPANDS THERAPEUTIC FOCUS AREAS; FIRST PATIENT DOSED WITH 212PBVMT-Α-NET IN THE MENINGIOMA COHORT OF A PHASE 1/2A STUDY
Source text: ID:nGNEbNnsRn
Further company coverage: CATX.A
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Perspective Therapeutics
See all newsBrief: Perspective Therapeutics Expands Therapeutic Focus Areas First Patient Dosed With Vmt-Α-Net In The Meningioma Cohort Of A Phase 1/2A Study
Brief: Perspective Therapeutics Q1 EPS USD -0.25
Perspective Therapeutics rises as experimental cancer drug shows promise
U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & Johnson
Brief: Perspective Therapeutics FY EPS USD -1.4